Paolo Milani

Jul 28, 2024 | nature.com | Antonio Chaves-Sanjuan |Melissa Milazzo |Giulia Mazzini |Paola Rognoni |Paolo Milani |Chiara Marabelli | +9 more

AbstractSystemic light chain (LC) amyloidosis (AL) is a disease where organs are damaged by an overload of a misfolded patient-specific antibody-derived LC, secreted by an abnormal B cell clone. The high LC concentration in the blood leads to amyloid deposition at organ sites. Indeed, cryogenic electron microscopy (cryo-EM) has revealed unique amyloid folds for heart-derived fibrils taken from different patients.

Jun 6, 2024 | onlinelibrary.wiley.com | Giovanni Palladini |Paolo Milani

In their paper the authors from the United Kingdom National Amyloidosis Center (NAC) show that patients with light chain (AL) amyloidosis who fail to respond to or relapse after cyclophosphamide, bortezomib and dexamethasone (VCD) can be effectively rescued with the combination of daratumumab, bortezomib and dexamethasone (DVD).